Navigation Links
Addition of bevacizumab to initial treatment for brain tumors does not extend patients' lives
Date:6/2/2013

Results of a randomized phase III clinical trial conducted by the Radiation Therapy Oncology Group (RTOG) determined that adding bevacizumab to initial treatment for glioblastoma (GBM) did not improve patient overall survival or progression-free survival,. Results were reported June 2 during the plenary session of the American Society of Clinical Oncology 2013 Annual Meeting.

Chicago, IllinoisGBM is the most common primary malignant brain tumor in adults and, despite treatment advances in recent years, the average survival of patients enrolled in clinical trials is less than 16 months and few patients live beyond five years. GBM is characterized by angiogenesisthe formation of new blood vessels that support tumor growth stimulated by the GBM-produced vascular endothelial growth factor A (VEGF-A). Bevacizumab is a monoclonal antibody that targets VEGF-A production to block the growth of tumor-derived blood vessels. "Clinical trials evaluating the addition of bevacizumab to standard treatment for recurrent glioblastoma demonstrated clinical benefit and led to the drug's FDA approval for this indication," says Mark Gilbert, MD, RTOG 0825 Principal Investigator and professor of neuro-oncology at The University of Texas MD Anderson Cancer Center, Houston, Texas. "Additionally, compelling preclinical data suggest that anti-angiogenic targeted therapies may normalize the tumor's rapidly forming and underdeveloped blood vessels, resulting in improved oxygen and chemotherapy delivery to the tumor and potentially enhancing radiotherapy and chemotherapy treatment," explains Gilbert. The RTOG 0825 study tested this hypothesis.

Six hundred and thirty-seven adult study participants were enrolled in the multicenter trial and randomized into one of two study arms, with treating physicians blinded to treatment assignment. All participants were treated with standard radiotherapy (RT) (60 Gy) and daily temozolomide. Bevacizumab (experimental arm) or a plac
'/>"/>

Contact: Shawn Farley
PR@acr.org
703-648-8936
American College of Radiology
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. Radiologists study necessity of additional imaging recommendations in PET/CT oncologic reports
2. Warmer soils release additional CO2 into atmosphere; Effect stabilizes over longer term
3. Additional research must be done to ensure safety of pit latrines, new study says
4. Evolution Marketing Research Grows its Practice with Addition of Three Key Industry Professionals
5. New data suggests HIV superinfection rate comparable to initial HIV infection
6. NLST: CT detects twice as many lung cancers as X-ray at initial screening exam
7. Breakthroughs in Chikungunya research from A*STAR spell new hope for better treatment and protection
8. Collaborative preclinical efficacy studies suggest a new target for drug addiction treatment
9. Genetic research develops tools for studying diseases, improving regenerative treatment
10. Step forward in research into new treatments for brain edema
11. Marshall University study may lead to new treatments for prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/16/2014)... have challenged conventional thinking on how the bowel lining ... for how bowel cancer starts. , The researchers produced ... regenerating the ,crypts, that are a feature of the ... in bowel cancer development, a controversial finding as scientists ... Using 3D imaging technologies, Dr Chin Wee Tan and ...
(Date:10/16/2014)... Virus causes severe respiratory tract infections and worldwide ... Scientists at VIB and Ghent University have succeeded ... this common virus infection. , Xavier Saelens ... paves the way for the development of a ... that causes suffering in numerous small children and ...
(Date:10/16/2014)... October 16, 2014 NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile ... technologies including Wocket™, the Smart Wallet, at the 13 ... is a leading global conference on the intersection of ... Mark Anderson , founder and publisher of the ...
Breaking Biology News(10 mins):Cryptic clues drive new theory of bowel cancer development 2New perspectives for development of an RSV vaccine 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3
... Researchers from LSU Health Sciences Center New Orleans ... of Child Health and Human Development (NICHD), Harvard School ... Medical School, have found for the first time that ... a week prior to pregnancy appears to significantly elevate ...
... - The inaugural Global Conference on Systems & ... Washington, DC, focuses on the convergence of complex large-scale ... The goal of the conference ... targeted complex systems, examined by domain, each successive year. ...
... early bird registration rates and register online now for ... WHAT: IOF WCO-ECCEO10 is a joint ... European Society for Clinical and Economic Aspects of Osteoporosis ... the world are expected to attend. The exciting scientific ...
Cached Biology News:Sugary cola drinks linked for first time to higher risk of gestational diabetes 2Sugary cola drinks linked for first time to higher risk of gestational diabetes 3First global conference on systems and enterprises at new Stevens location, Washington, DC, Dec. 3-4 2
(Date:10/22/2014)... Massachusetts (PRWEB) October 22, 2014 ... announced the release of a new infographic, Understanding ... to create a beautifully designed, easy to follow informative ... transmission, areas of outbreak, symptoms and prevention. , "As ... discovered that the 2014 Ebola outbreak represents not only ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Currently ... Sartorius, A & D Weighing, Rice Lake, and ... Semi-Micro Balance . The Sartorius CPA Semi-Micro Balance ... affordable high-quality, precise, and user-friendly laboratory balance. , ... laboratory equipment, their laboratory balances are well known ...
(Date:10/22/2014)... Hill, SC (PRWEB) October 22, 2014 ... expansion of its cardiovascular pharmacogenetics menu, which enables ... patient outcomes. With PCLS’s evidence-based results, healthcare ... needs and optimize their therapy, while minimizing risks ... In the U.S., according to the FDA [1] ...
(Date:10/22/2014)... Oct. 22, 2014   Synthetic Biologics, Inc. ... therapies for serious infections and diseases, announced today that ... Notice of Allowance for a composition of matter patent ... difficile program, SYN-004. This is Synthetic Biologics, first ... U.S. and adds to the Company,s extensive C. ...
Breaking Biology Technology:Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4
... 2010 Shire plc (LSE: SHP,NASDAQ: SHPGY ) the global specialty biopharmaceutical company, announces,results for the three months to March 31, 2010 . ... ... $718 million ... Total revenues ...
... , April 29, 2010 According to ... by,MarketsandMarkets ( http://www.marketsandmarkets.com ), The global oncology,biomarker market is ... 2009 to $9.5,billion in 2014 at a ... Oncology,Biomarkers Market report analyzes the oncology biomarkers diagnostics and,discovery ...
... also known as hypertension, is a serious health risk factor ... the molecular basis of the disease remains poorly understood. ... ( www.genome.org ), scientists have sequenced the genome of ... variants that will help researchers to understand causes of the ...
Cached Biology Technology:Shire's Replenished Portfolio Drives Excellent Quarterly Performance 2Shire's Replenished Portfolio Drives Excellent Quarterly Performance 3Shire's Replenished Portfolio Drives Excellent Quarterly Performance 4Shire's Replenished Portfolio Drives Excellent Quarterly Performance 5Shire's Replenished Portfolio Drives Excellent Quarterly Performance 6Shire's Replenished Portfolio Drives Excellent Quarterly Performance 7Shire's Replenished Portfolio Drives Excellent Quarterly Performance 8Shire's Replenished Portfolio Drives Excellent Quarterly Performance 9Shire's Replenished Portfolio Drives Excellent Quarterly Performance 10Shire's Replenished Portfolio Drives Excellent Quarterly Performance 11Shire's Replenished Portfolio Drives Excellent Quarterly Performance 12Shire's Replenished Portfolio Drives Excellent Quarterly Performance 13Shire's Replenished Portfolio Drives Excellent Quarterly Performance 14Shire's Replenished Portfolio Drives Excellent Quarterly Performance 15Shire's Replenished Portfolio Drives Excellent Quarterly Performance 16Shire's Replenished Portfolio Drives Excellent Quarterly Performance 17Shire's Replenished Portfolio Drives Excellent Quarterly Performance 18Shire's Replenished Portfolio Drives Excellent Quarterly Performance 19Shire's Replenished Portfolio Drives Excellent Quarterly Performance 20Shire's Replenished Portfolio Drives Excellent Quarterly Performance 21Shire's Replenished Portfolio Drives Excellent Quarterly Performance 22Shire's Replenished Portfolio Drives Excellent Quarterly Performance 23Shire's Replenished Portfolio Drives Excellent Quarterly Performance 24Shire's Replenished Portfolio Drives Excellent Quarterly Performance 25Shire's Replenished Portfolio Drives Excellent Quarterly Performance 26Shire's Replenished Portfolio Drives Excellent Quarterly Performance 27Shire's Replenished Portfolio Drives Excellent Quarterly Performance 28Shire's Replenished Portfolio Drives Excellent Quarterly Performance 29Shire's Replenished Portfolio Drives Excellent Quarterly Performance 30Shire's Replenished Portfolio Drives Excellent Quarterly Performance 31Shire's Replenished Portfolio Drives Excellent Quarterly Performance 32Shire's Replenished Portfolio Drives Excellent Quarterly Performance 33MarketsandMarkets: Global Oncology Biomarkers Market Worth US$9.5 Billion by 2014 2MarketsandMarkets: Global Oncology Biomarkers Market Worth US$9.5 Billion by 2014 3MarketsandMarkets: Global Oncology Biomarkers Market Worth US$9.5 Billion by 2014 4
4-Hydroxy-3-nitrophenylacetyl hapten is conjugated to KLH (Keyhole Limpet Hemocyanin) lysine through amide bonds....
Estrogen Receptor (ER) Competitor Assay Kits Green for Estrogen Receptors-alpha and -beta (ER-Alpha and ER-Beta) are ideal for screening novel estrogen receptor binding compounds and endocrine disrup...
Human Aminopeptidase P2/XPNPEP2 Affinity Purified PAb ENTREZ GeneID: 7512...
in vitro Translation, Accessory Products...
Biology Products: